KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Medical Sciences / 2015 / Cilt: 45 - Sayı: 3

Serum Lp-PLA2: as a novel viewpoint in periodontal treatment of hyperlipidaemics

ÖZLEM FENTOĞLU
FATMA YEŞİM KIRZIOĞLU
MEMDUHA TÖZÜM BULUT
ŞİVGE KURGAN
HAVVA KOÇAK
RECEP SÜTCÜ
BANU KALE KÖROĞLU
MERAL GÜNHAN
Sayfa
619–626
Yayın Tarihi
2015-08-13
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

These findings may be important regarding the therapeutic strategies for hyperlipidaemics with periodontitis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: To evaluate the effects of periodontal treatment on serum lipoprotein-associated phospholipase A2 (Lp-PLA2) and C-reactive protein (CRP) levels in hyperlipidaemic patients with periodontitis.
📊
Temel Bulgular & Veri:Materials and methods: The study included 52 hyperlipidaemics and 28 systemically healthy controls (C) with periodontitis.
💡
Sonuç & Katkı:These findings may be important regarding the therapeutic strategies for hyperlipidaemics with periodontitis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Periodontal treatment · hyperlipidaemia · periodontitis

Özet

Background/aim: To evaluate the effects of periodontal treatment on serum lipoprotein-associated phospholipase A2 (Lp-PLA2) and C-reactive protein (CRP) levels in hyperlipidaemic patients with periodontitis. Materials and methods: The study included 52 hyperlipidaemics and 28 systemically healthy controls (C) with periodontitis. Of the 52 hyperlipidaemics, 29 received a suggested diet (HD), and 23 of them were prescribed statin (HS). Clinical periodontal parameters, serum lipids, Lp-PLA2, and CRP levels were assessed at the baseline and 2 months after the completion of the nonsurgical periodontal treatment (2MPT). Serum parameters were also evaluated 1 week following the periodontal treatment (1WPT). Results: At the baseline, patients in the HS group had a higher percentage of bleeding on probing than those in the C and HD groups. Hyperlipidaemics had higher serum triglyceride levels than the control group at 2MPT compared to the baseline. At 2MPT, the levels of Lp-PLA2 in the HS group were significantly higher compared to the baseline and 1WPT. There were no statistically significant differences in CRP levels between study periods for all groups. Conclusion: The periodontal treatment may affect the inflammatory control of hyperlipidaemic patients with periodontitis via increased Lp-PLA2 levels and severity of the impaired lipid metabolism. These findings may be important regarding the therapeutic strategies for hyperlipidaemics with periodontitis.

Abstract

Background/aim: To evaluate the effects of periodontal treatment on serum lipoprotein-associated phospholipase A2 (Lp-PLA2) and C-reactive protein (CRP) levels in hyperlipidaemic patients with periodontitis. Materials and methods: The study included 52 hyperlipidaemics and 28 systemically healthy controls (C) with periodontitis. Of the 52 hyperlipidaemics, 29 received a suggested diet (HD), and 23 of them were prescribed statin (HS). Clinical periodontal parameters, serum lipids, Lp-PLA2, and CRP levels were assessed at the baseline and 2 months after the completion of the nonsurgical periodontal treatment (2MPT). Serum parameters were also evaluated 1 week following the periodontal treatment (1WPT). Results: At the baseline, patients in the HS group had a higher percentage of bleeding on probing than those in the C and HD groups. Hyperlipidaemics had higher serum triglyceride levels than the control group at 2MPT compared to the baseline. At 2MPT, the levels of Lp-PLA2 in the HS group were significantly higher compared to the baseline and 1WPT. There were no statistically significant differences in CRP levels between study periods for all groups. Conclusion: The periodontal treatment may affect the inflammatory control of hyperlipidaemic patients with periodontitis via increased Lp-PLA2 levels and severity of the impaired lipid metabolism. These findings may be important regarding the therapeutic strategies for hyperlipidaemics with periodontitis.

🔖

Bu Makaleye Atıf Yap

FENTOĞLU, Ö., KIRZIOĞLU, F. Y., BULUT, M. T., KURGAN, Ş., KOÇAK, H., SÜTCÜ, R., KÖROĞLU, B. K., GÜNHAN, M. (2015). Serum Lp-PLA2: as a novel viewpoint in periodontal treatment of hyperlipidaemics. Turkish Journal of Medical Sciences, Cilt: 45 - Sayı: 3, 619–626. https://ajindex.com/articles/113941

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844–2850.
  2. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983; 34: 141– 212. Yang EH, McConnell JP, Lennon RJ, Barsness GW, Pumper G, Hartman SJ, Rihal CS, Lerman LO, Lerman A. Lipoprotein- associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2006; 26: 106–111.
  3. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 2523–2529.
  4. Lösche W, Marshai GJ, Apatzidou DA, Krause S, Kocher T, Kinane DF. Lipoprotein associated phospholipase A2 and plasma lipids in patients with destructive periodontal disease. J Clin Periodontol 2005; 32: 640–644. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001; 38:189–197.
  5. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. P Natl Acad Sci USA 2002; 99: 13043–13048.
  6. Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses on C reactive protein in relation to periodontitis. J Clin Periodontol 2008; 35: 277–290.
  7. Noack B, Jachmann I, Roscher S, Sieber L, Kopprasch S, Lück C, Hanefeld M, Hoffmann T. Metabolic diseases and their possible link to risk indicators of periodontitis. J Periodontol 2000; 71: 898–903.
  8. Fentoğlu Ö, Öz G, Taşdelen P, Uskun E, Aykaç Y, Bozkurt FY. Periodontal status in subjects with hyperlipidaemia. J Periodontol 2009; 80: 267–273.
  9. Awartani F, Atassi F. Evaluation of periodontal status in subjects with hyperlipidaemia. J Contemp Dent Pract 2010; 11: 33–40.
  10. Oz SG, Fentoglu O, Kilicarslan A, Guven GS, Tanrover MD, Aykac Y, Sozen T. Beneficial effects of periodontal treatment on metabolic control of hypercholesterolemia. South Med J 2007; 100: 686–691.
  11. Fentoğlu Ö, Sözen T, Öz SG, Kale B, Sönmez Y, Öztürk Tonguç M, Gürgan CA, Aykaç Y, Kırzıoğlu FY. Short-term effects of periodontal therapy as an adjunct to anti-lipaemic treatment. Oral Dis 2010; 16: 648–654.
  12. Fentoğlu Ö, Köroğlu BK, Hiçyılmaz H, Sert T, Özdem M, Sütçü R, Tamer MN, Orhan H, Ay ZY, Öztürk Tonguç M et al. Pr